Navigation Links
Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
Date:2/14/2008

PITTSBURGH, Feb. 14 /PRNewswire-FirstCall/ -- In response to several inquiries, Mylan Inc. (NYSE: MYL) confirmed today that its matrix design Fentanyl Transdermal System (FTS) is not part of the widespread recall being conducted by Ortho-McNeil-Janssen Pharmaceuticals, Inc. Ortho-McNeil reported that all lots of 25 mcg/hr Duragesic(R) CII patches sold by PriCara in the United States and all 25 mcg/hr Fentanyl patches sold by Sandoz Inc. in the United States are being voluntarily recalled as a precaution from wholesalers and pharmacies because they may have a cut along one side of the drug reservoir within the patch. The result is possible release of Fentanyl gel from the gel reservoir into the pouch in which the patch is packaged, exposing patients or caregivers directly to Fentanyl gel.

Unlike all other U.S. marketed Fentanyl patches, Mylan's FTS is a matrix patch, not a reservoir patch, and therefore does not leak.

Mylan Vice Chairman and CEO Robert J. Coury commented: "We have always believed that our Fentanyl Transdermal System is differentiated from all other Fentanyl patches in the U.S. market because of its unique matrix design. This is an important product characteristic that should be recognized and understood when choosing a Fentanyl Transdermal System."

Mylan's FTS was the first generic Class II narcotic transdermal product approved by the U.S. Food and Drug Administration.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey, L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas. For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Restores Availability of Generic Levothyroxine in Florida
2. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
3. Mylan Declares Quarterly Preferred Stock Dividend
4. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
5. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
6. Mylan Sets Date of 2008 Annual Meeting
7. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
8. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
9. Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock
10. Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock
11. Mylan Announces Appointment of Joseph F. Haggerty as Senior Vice President and Global General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” (published by ... Schanssema describes the tragedies he saw, as well as his struggles with grief and ... unsure of the career path he wanted to take, found fulfillment in a career ...
(Date:2/24/2017)... , ... February 24, 2017 , ... The International Association ... annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected from ... be showcased and the winner revealed at the 31st annual iaedp Symposium, March 22 ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head Over ... on February 12th. Ms. Esparza qualified into this prestigious status after winning ... in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in the ...
(Date:2/23/2017)... ... ... The 89th Academy Awards will be celebrated this weekend, which means it’s also ... We invite you to enjoy our 11th annual tongue-in-cheek “salute” to the shoddiest think ... American Progress (CAP), for its report, Lessons From State Performance on NAEP: Why Some ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael ... “Mama June: From Not to Hot,” which will begin airing on February 24, 2017. ... to millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” The ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017  Genesis Healthcare Services has merged with Hospice ... by Bill Monast , President and CEO of ... Nathan Feltman , executives with Home Health Depot, Inc., ... This acquisition helps Hospice Cloud maintain its ... durable medical equipment (DME) solutions for the hospice industry. ...
(Date:2/23/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device ... for the urology market, will release financial results for ... 2016 before the market open on Thursday, March 9, ... conference call and webcast to discuss its financial results ... 11:00 a.m. Eastern Time (10:00 a.m. Central Time). ...
(Date:2/23/2017)... Nevro Corp. (NYSE: NVRO), a global medical device ... of chronic pain, today reported financial results for the three ... 2016 Accomplishment & Highlights: Achieved revenue ... of 228% as reported, over the prior year ... 612% over the prior year International revenue ...
Breaking Medicine Technology: